Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer’s Disease Risk to Include Saliva Samples
Pioneering polygenic risk scoring approach verified for banked DNA, blood and saliva samples
8th May 2018: Oxford & Manchester, UK and Atlanta, GA. Cytox, a precision medicine testing company which today is commercializing polygenic risk scoring (PRS) and other approaches for assessing genetic risk for developing Alzheimer’s disease, has collaborated with integrated genomics and genetics leader AKESOgen to verify the performance of the Cytox genoBAR™ test with saliva samples.
The Cytox genoBAR research test is intended to help pharma, biotech, and sponsors of large cohort studies reduce the time and high cost associated with identifying and stratifying subjects for clinical trials and large-population research, which can take more than six months and run tens of thousands of dollars per participant. The work performed by Cytox and AKESOgen resulted in over 99% concordance between the SNPs used in the PRS identified from blood and saliva samples collected from the same subjects and run on the Cytox variaTECT™ microarray on the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform from Thermo Fisher Scientific. The saliva samples were collected using the DNA Genotek DNA saliva collection kit. The results of this verification study will provide an additional means to collect DNA from prospective clinical trial and cohort subjects and opens the possibility of screening even larger population groups for disease risk.
“The extension of our test to include saliva samples in addition to blood samples and biobanked DNA represents a significant step forward,” commented Dr Richard Pither, CEO of Cytox, “Our customers in pharma and biotech now have the ability to collect larger numbers of samples in a highly efficient and non-invasive way, opening the doors to the cost-effective screening of tens to hundreds of thousands of prospective clinical study participants, or still larger population networks associated with regional healthcare centres or national dementia programmes.”
Dr Mark Bouzyk, Chief Scientific Officer at AKESOgen, added, “The collaboration between AKESOgen and Cytox aims to ensure the highest accuracy possible across all the biological samples types generally used for genetic analysis. We believe these results and our partnership with Cytox will eventually result in more effective screening and diagnosis for those patients impacted by Alzheimer’s disease.”
Cytox Group Limited is a precision medicine information company whose mission is to transform how treatments are developed, people are screened and therapies are prescribed for the most prevalent neurological diseases, including Alzheimer’s disease. Alzheimer’s disease today impacts over 46 million people globally, reaching 74.7 million in 2030 and projected to grow to over 131 million people by 2050 with an economic impact to exceed two trillion dollars. Leveraging the proprietary Cytox variaTECT™ SNP genotyping array, Cytox SNPfitR™ algorithm for polygenic risk scoring and running on the proven power and scalability of the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument platform, the company offers genomic profiling testing assays and services to early access collaborators in academia and Biopharma pursuing clinical research and drug development. The service is designed to help researchers and clinicians access the biology and genetics behind dementia, stratify patients to enable more cost effective and information rich clinical trials, and ultimately establish risk for cognitive decline and matching with the most appropriate targeted therapy.
The company is headquartered in the United Kingdom with assays and services available to early access collaborators globally. For more information, please visit www.cytoxgroup.com and follow the company on Twitter at @CytoxDx and on LinkedIn. Cytox’s assay and testing services are for research use only and not for use in diagnostic procedures.
AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.
Richard Pither, CEO
+44(0) 1865 338018
Mark Bouzyk, CSO
+1 770 542 0890